Table 1.
Characteristics of the study sample.
| Total (N = 27) | |
|---|---|
| Age at symptom onset (median [Q1, Q3], years) | 65.0 [54.0, 71.0] |
| Male sex (n, %) | 12/27 (44.4) |
| White ethnicity (n, %) | 26/27 (96.3) |
| Follow‐up time from symptom onset (median [Q1, Q3], months) | 53.9 [11.2, 102.2] |
| Cancer (n, %) | 15/27 (55.6) |
| SCLC (n, %) | 8/15 (53.3) |
| Thymoma (n, %) | 4/15 (26.7) |
| Other (n, %) | 3/15 (20.0) |
| Without cancer (n, %) | 12/27 (44.4) |
| Pulmonary nodules 1 (n, %) | 7/12 (58.3) |
| Smoking history (n, %) | 22/27 (81.5) |
| CSF with inflammation 1 (n, %) | 9/11 (81.8) |
| Deceased (n, %) | 13/27 (48.1) |
| Due to cancer (n, %) | 5/13 (38.5) |
| Due to neurologic cause (n, %) | 1/13 (7.7) |
| Other causes (n, %) | 7/13 (53.8) |
| Received immunotherapy (n, %) | 15/27 (55.6) |
| Acute immunotherapy (IVMP, IVIG or PLEX) (n, %) | 11/15 (73.3) |
| Cyclophosphamide (n, %) | 3/15 (20.0) |
| Mycophenolate mofetil (n, %) | 1/15 (6.7) |
| Other (n, %) | 4/15 (26.7) |
| Wheelchair dependence due to PND (n, %) | 10/27 (37.0) |
| mRS at first visit (median [Q1, Q3]) | 2.0 [2.0, 3.0] |
| Moderate–severe mRS at first visit (mRS 3–5) (n, %) | 11/27 (40.7) |
| mRS at last visit (median [Q1, Q3]) | 3.0 [2.0, 4.0] |
| Moderate–severe mRS at last visit (mRS 3–5) (n, %) | 18/27 (66.7) |
| Clinical phenotypes | |
| Cerebellar ataxia (n, %) | 11/27 (40.7) |
| Myelopathy (n, %) | 8/27 (29.6) |
| Polyneuropathy/radiculopathy (n, %) | 14/27 (51.9) |
| Myasthenia (n, %) | 7/27 (25.9) |
| Autoimmune encephalopathy (n, %) | 7/27 (25.9) |
| Optic neuropathy (n, %) | 6/27 (22.2) |
Statistics presented as median [P25, P75], N (column %).
Abbreviations: SCLC, small cell lung cancer; CSF, cerebrospinal fluid; MRI, magnetic resonance imaging; IVMP, intravenous methylprednisolone; IVIG, intravenous immunoglobulin; PLEX, plasma exchange; mRS, modified Rankin Scale.
1
Data are not available for all subjects. Missing values: Pulmonary nodules = 4; CSF = 16.